Merit Medical Systems (MMSI) Q4 2024 earnings summary

Executive summary

• Q4 2024 revenue reached $355.2 million, up 9.4% year-over-year; full-year revenue was $1.36 billion, up 7.9%, exceeding prior guidance.

• Full year 2024 saw over 8% constant currency revenue growth, with 6% organic growth, record non-GAAP gross and operating margins, and free cash flow up 67% to $185.7 million.

• U.S. revenue led growth, up 13.3% in Q4 and 10.2% for FY 2024; international revenue up 4.2% in Q4 and 4.8% for FY 2024.

• Strong execution in both organic and acquired product lines, with notable contributions from EndoGastric Solutions and Cook Medical acquisitions.

• Non-GAAP net income for Q4 2024 increased 30.6% to $56.3 million; FY 2024 non-GAAP net income up 23.4% to $205.4 million.

Financial highlights

• Q4 non-GAAP operating profit grew 30% year-over-year; non-GAAP operating margin reached 19.6%, up 305 basis points.

• Q4 non-GAAP EPS grew 25.8% to $0.93 per share; net income was $56.3 million, up from $43.1 million in Q4 2023.

• Q4 GAAP gross margin improved to 48.7% from 46.4% year-over-year; non-GAAP gross margin reached 53.5%.

• Free cash flow for FY 2024 was $185.7 million, up 67% year-over-year.

• Operating cash flow for FY 2024 was $220.8 million; capital expenditures totaled $35.1 million.

Outlook and guidance

• FY2025 revenue guidance: $1.470–$1.490 billion, up 8–10% year-over-year; constant currency growth of 8.6%–10.1%.

• Cardiovascular segment expected to grow 7–9%; Endoscopy segment projected to grow 36–40%.

• Non-GAAP EPS guidance for 2025 is $3.58–$3.70, up 4–7% year-over-year.

• Free cash flow expected to be at least $150 million in 2025, with $90–$100 million in CapEx for a new distribution center.

• Q1 2025 revenue growth expected at 8.2%–9.7% GAAP, 8.8%–10.3% constant currency; non-GAAP EPS $0.73–$0.76.